The Interplay between cancer biology and the endocannabinoid system - significance for cancer risk, prognosis and response to treatment

Abstract

The various components of the endocannabinoid system (ECS), such as the cannabinoid receptors (CBRs), cannabinoid ligands, and the signalling network behind it, are implicated in several tumour-related states, both as favourable and unfavourable factors. This review analyses the ECS's complex involvement in the susceptibility to cancer, prognosis, and response to treatment, focusing on its relationship with cancer biology in selected solid cancers (breast, gastrointestinal, gynaecological, prostate cancer, thoracic, thyroid, CNS tumours, and melanoma). Changes in the expression and activation of CBRs, as well as their ability to form distinct functional heteromers a ect the cell's tumourigenic potential and their signalling properties, leading to pharmacologically di erent outcomes. Thus, the same ECS component can exert both protective and pathogenic e ects in di erent tumour subtypes, which are often pathologically driven by di erent biological factors. The use of endogenous and exogenous cannabinoids as anti-cancer agents, and the range of e ects they might induce (cell death, regulation of angiogenesis, and invasion or anticancer immunity), depend in great deal on the tumour type and the specific ECS component that they target. Although an attractive target, the use of ECS components in anti-cancer treatment is still interlinked with many legal and ethical issues that need to be considered.